Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.
Serologic testing is the principal means of laboratory diagnosis of Lyme disease. Current recommendations include using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay, followed by a western immunoblot assay for specimens yielding positive or equivocal results.
On July 29, 2019, the Food and Drug Administration cleared several Lyme disease serologic assays with new indications for use, allowing for an EIA rather than western
Gut has published population results from NHANES population study showing that the prevalence of fatty liver disease is rising in the US and is driven by obesity and diabetes.
Dr. John Cush RheumNow
7 years 2 months ago
Chance over metrics? If your metrics are not predictive, then you have failed metrics and the opportunity to refine, Change or rethink. Should you randomly chose a drug from equivalent drugs or use data to make a better choice? https://t.co/a7GibSmOWv
Dr. John Cush RheumNow
7 years 2 months ago
UT Southwestern Super Hepatologist Dr Will Lee lecturing on drug induced liver injury (DILI) shows DILI is not increase with NASH/NAFLD https://t.co/1Kt7hFhUx1
Dr. John Cush RheumNow
7 years 2 months ago
Nurses' Health Study II shows high gluten intake is not assoc w/ a greater risk of Psoriasis (HR 1.15;0.98-1.36), Psoriatic arthritis (HR 1.12;0.78-1.62) or Atopic dermatitis (HR 0.91; 0.66-1.25); 85,185 Pso, 85,324 PsA & 63,443 atopic dermatitis patients. https://t.co/P1eWGZZqKl
Dr. John Cush RheumNow
7 years 2 months ago
Kaiser study from N California shows increasing trend in cannabis use w/ #pregnancy. Sample of 367 403 pregnancies in 276 991 women between 2009-18, cannibis use rose from 1.95% to 3.38% - ?increasing acceptance & decreasing perceptions of harms? https://t.co/VdOPrCsZQ1
Dr. John Cush RheumNow
7 years 2 months ago
Ah yes...lifestyle is certainly a BIG issue in RA, especially when there's a poor outcome. Besides life in the fast lane - other bad advice for RA - Take It Easy, Take It to the Limit
& Tequila Sunrise. Good Advice? Take it easy! https://t.co/uKkRveDYzp
The German National Database (NDB) has reviewed their experience in the care and quality of life of inflammatory rheumatic disease patients snce 1993, showing improved use of metrics, improved outcomes and a changing profile of biologic and anti-rheumatic drug use.
Dr. John Cush RheumNow
7 years 2 months ago
Cross sectional analysis of ~3000 and meta-analysis (14 studies) finds #gout has a higher risk of hypothyroidism, esp in female gout pts (OR=2.44;1.15-5.17); Metaanalysis ^risk hypothyroidism in gout (OR=1.51) and hyperuricemic pts (OR=1.34) https://t.co/1w3xfHqryJ
Among patients with pre-existing autoimmune diseases who developed cancer and were treated with immune checkpoint inhibitors (ICI), flares of the underlying disease and other immune-related adverse events were common, a retrospective study conducted in France showed.
Dr. John Cush RheumNow
7 years 2 months ago
Lilly announces the results of its phase 4 trial comparing Taltz (IL-17) to Tremfya (IL-23) in mod-severe plaque psoriasis. Taltz had superior skin clearance (PASI 100) at week 12, better PASI 75 at week 2 and PASI 90 at weeks 4 and 8. https://t.co/GzfZoepUrK
Dr. John Cush RheumNow
7 years 2 months ago
"WAR on RA - Part 4: Desperado" is featured on RheumNow. Why the Eagles and Glenn Fry's death should inspire us to better, greater, more and other superlatives in RA. https://t.co/dgShcQpWHP
The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.
Accelerated bone loss has been shown to be an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown.
